Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia.

Antinociception Chronic pain JMV431 (Pubchem SID 135652223) Metabolic stability NT(8-13) (PubChem CID 5311318) PD149163 (PubChem CID 73064239) Silaproline TMSAla Unnatural amino acid

Journal

Behavioural brain research
ISSN: 1872-7549
Titre abrégé: Behav Brain Res
Pays: Netherlands
ID NLM: 8004872

Informations de publication

Date de publication:
07 05 2021
Historique:
received: 01 07 2020
revised: 10 02 2021
accepted: 11 02 2021
pubmed: 20 2 2021
medline: 27 1 2022
entrez: 19 2 2021
Statut: ppublish

Résumé

The endogenous tridecapeptide neurotensin (NT) has emerged as an important inhibitory modulator of pain transmission, exerting its analgesic action through the activation of the G protein-coupled receptors, NTS1 and NTS2. Whereas both NT receptors mediate the analgesic effects of NT, NTS1 activation also produces hypotension and hypothermia, which may represent obstacles for the development of new pain medications. In the present study, we implemented various chemical strategies to improve the metabolic stability of the biologically active fragment NT(8-13) and assessed their NTS1/NTS2 relative binding affinities. We then determined their ability to reduce the nociceptive behaviors in acute, tonic, and chronic pain models and to modulate blood pressure and body temperature. To this end, we synthesized a series of NT(8-13) analogs carrying a reduced amide bond at Lys

Identifiants

pubmed: 33607165
pii: S0166-4328(21)00077-2
doi: 10.1016/j.bbr.2021.113189
pii:
doi:

Substances chimiques

Analgesics 0
Neurotensin 39379-15-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

113189

Subventions

Organisme : CIHR
ID : FDN-148413
Pays : Canada

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Mélanie Vivancos (M)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada. Electronic address: melanie.vivancos@usherbrooke.ca.

Roberto Fanelli (R)

Institut des Biomolécules Max Mousseron (IBMM), UMR-CNRS 5247, Université Montpellier, ENSCM, Montpellier, France. Electronic address: robyfanelli@hotmail.it.

Élie Besserer-Offroy (É)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada. Electronic address: ebesserer@mednet.ucla.edu.

Sabrina Beaulieu (S)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada. Electronic address: sabrina.beaulieu@usherbrooke.ca.

Magali Chartier (M)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.

Martin Resua-Rojas (M)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada. Electronic address: martin.resua-rojas@usherbrooke.ca.

Christine E Mona (CE)

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA, USA. Electronic address: cmona@mednet.ucla.edu.

Santo Previti (S)

Institut des Biomolécules Max Mousseron (IBMM), UMR-CNRS 5247, Université Montpellier, ENSCM, Montpellier, France. Electronic address: spreviti@unime.it.

Emmanuelle Rémond (E)

Institut des Biomolécules Max Mousseron (IBMM), UMR-CNRS 5247, Université Montpellier, ENSCM, Montpellier, France. Electronic address: emmanuelle.remond@umontpellier.fr.

Jean-Michel Longpré (JM)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada. Electronic address: jean-michel.longpre@usherbrooke.ca.

Florine Cavelier (F)

Institut des Biomolécules Max Mousseron (IBMM), UMR-CNRS 5247, Université Montpellier, ENSCM, Montpellier, France. Electronic address: florine.cavelier@umontpellier.fr.

Philippe Sarret (P)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada. Electronic address: philippe.sarret@usherbrooke.ca.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH